
NTLA
Intellia Therapeutics Inc
Biotechnology
Intellia Therapeutics Inc (NTLA) Stock News
The latest NTLA headlines and market coverage — 1 recent story, updated throughout the day.
- Zacks Investment Research·Neutral
Intellia Therapeutics (NTLA) Soars 7.6%: Is Further Upside Left in the Stock?
Intellia Therapeutics shares rallied 7.6% following FDA acceptance of its CRISPR-based HAE treatment under Priority Review with a March 2027 decision date, and a $400 million debt facility secured in September. However, the stock carries a Hold rating as earnings estimate revisions remain unchanged, and the company faces declining revenues and quarterly losses.